Key result
Prophylactic aspirin use for 10 years in average-risk individuals aged 50-65 years yields a 7-9% relative reduction in cancer, MI, or stroke events and a 4% relative reduction in all deaths.
Why the study?
Does prophylactic aspirin use reduce cancer incidence, mortality, and cardiovascular events in the general population?
Systematic Review
Does prophylactic aspirin use reduce cancer incidence, mortality, and cardiovascular events in the general population?
Effect estimate: 7-9% relative reduction
Prophylactic aspirin use for 10 years in average-risk individuals aged 50-65 years yields a net reduction in cancer, cardiovascular events, and overall mortality, presenting a favorable benefit-harm profile.
No takes yet. Share an insight, caveat, or question.
Supports aspirin prophylaxis in average-risk adults aged 50-65; confirms net benefit on cancer, MI, stroke, and mortality.
Cuzick et al. (2014) conducted a systematic review in general population. Prophylactic aspirin was evaluated on cancer, myocardial infarction or stroke events (7-9% relative reduction). Prophylactic aspirin use for 10 years in average-risk individuals aged 50-65 years yields a 7-9% relative reduction in cancer, MI, or stroke events and a 4% relative reduction in all deaths.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: